Journal Article

Safety and efficacy of Wharton's jelly‐derived mesenchymal stem cells with teriparatide for osteoporotic vertebral fractures: A phase I/IIa study

Choi, Hyemin, Han, Inbo, Kyung, Jae Won, Kim, Kwang Gi, Sohn, Seil, Ahn, Tae‐Keun, Shim, JeongHyun, Choi, Un‐Yong, Shin, Dong‐Eun, Lim, Sang Heon, Kim, Kyoung‐Tae, Choi, Hye Jeong

2021

Overview

Osteoporotic vertebral compression fractures (OVCFs) are serious health problems. We conducted a randomized, open‐label, phase I/IIa study to determine the feasibility, safety, and effectiveness of Wharton's jelly‐derived mesenchymal stem cells (WJ‐MSCs) and teriparatide (parathyroid hormone 1‐34) in OVCFs. Twenty subjects with recent OVCFs were randomized to teriparatide (20 μg/day, daily subcutaneous injection for 6 months) treatment alone or combined treatment of WJ‐MSCs (intramedullary [4 × 107 cells] injection and intravenous [2 × 108 cells] injection after 1 week) and teriparatide (20 μg/day, daily subcutaneous injection for 6 months). Fourteen subjects (teriparatide alone, n = 7; combined treatment, n = 7) completed follow‐up assessment (visual analog scale [VAS], Oswestry Disability Index [ODI], Short Form‐36 [SF‐36], bone mineral density [BMD], bone turnover measured by osteocalcin and C‐terminal telopeptide of type 1 collagen, dual‐energy x‐ray absorptiometry [DXA], computed tomography [CT]). Our results show that (a) combined treatment with WJ‐MSCs and teriparatide is feasible and tolerable for the patients with OVCFs; (b) the mean VAS, ODI, and SF‐36 scores significantly improved in the combined treatment group; (c) the level of bone turnover markers were not significantly different between the two groups; (d) BMD T‐scores of spine and hip by DXA increased in both control and experimental groups without a statistical difference; and (e) baseline spine CT images and follow‐up CT images at 6 and 12 months showed better microarchitecture in the combined treatment group. Our results indicate that combined treatment of WJ‐MSCs and teriparatide is feasible and tolerable and has a clinical benefit for fracture healing by promoting bone architecture. Clinical trial registration: https://nedrug.mfds.go.kr/, MFDS: 201600282‐30937. Combined treatments of Wharton's jelly‐derived mesenchymal stem cells (WJ‐MSCs) and parathyroid hormone (PTH) increased the T‐scores of the spine and hip and improved the microarchitecture in the fractured vertebral body. These effects provided satisfactory improvement of pain, function, and quality of life for patients with osteoporotic vertebral compression fractures (OVCFs). Combined treatment of WJ‐MSCs and PTH is feasible and tolerable and has a clinical benefit for treatment of OVCFs.

• Publisher: John Wiley & Sons, Inc,Oxford University Press
• Subject: Apoptosis / Back pain / Bisphosphonates / Bone Density / Bone Density Conservation Agents - therapeutic use / Bone healing / Bone mineral density / Bone turnover / Clinical trials / Collagen / Compression / Computed tomography / Disease prevention / Drugs / Dual energy X-ray absorptiometry / Feasibility studies / Fractures / Fractures, Compression - therapy / Good Manufacturing Practice / Human Clinical / Humans / Informed consent / Intravenous administration / Mesenchymal Stem Cell Transplantation / Mesenchymal stem cells / Metabolism / Mortality / Osteocalcin / Osteoporosis / Osteoporotic Fractures - therapy / Parathyroid / Parathyroid hormone / Spinal Fractures - therapy / Spine / Stem cells / teriparatide / Teriparatide - therapeutic use / Trauma / Vertebrae / vertebral compression fracture / Wharton Jelly - cytology / Wharton's jelly